Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Reticulocyte Hemoglobin Equivalent-guided Versus Transferrin Saturation-guided Iron Supplement Protocol in Hemodialysis Patients: A Cluster Randomized Controlled Trial

NCT06906835 is registered in ClinicalTrials.gov with King Chulalongkorn Memorial Hospital as lead sponsor.

NCT NCT06906835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06906835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Reticulocyte Hemoglobin Equivalent-guided Versus Transferrin Saturation-guided Iron Supplement Protocol in Hemodialysis Patients: A Cluster Randomized Controlled Trial
Lead sponsor
King Chulalongkorn Memorial Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
January 31, 2025
Completion date
September 30, 2025
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia in end stage renal disease, hemodialysis